{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:36:59Z","timestamp":1793039819146,"version":"4.5.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Stroke can occur at any age, and the effects can last for the remaining lifetime. To minimize the clinical and economic burden of stroke, we need to develop and test new treatments that have the potential to improve outcomes for people with stroke. Early-phase trials are foundational to testing new treatments in medicine. Early-phase trials encompass dose-ranging, dose-screening, and dose-finding noncomparative designs. A dose-ranging trial aims to establish the safe and tolerable dose range for a given investigational intervention in a target population to progress to a dose-screening or dose-finding trial that systematically identifies an intervention dose(s) in the target population that has signal of efficacy, feasibility, safety, and tolerability. Such designs originated in the oncology field and are gaining prominence in stroke literature. In this article, we first outline the features that differentiate the contribution of early-phase trials from late-phase trials and present a stepwise development program approach to frame our discussion. We then review early-phase trial terminology, discuss the characteristics of early-phase trials and high-quality reporting, and the role, value, and contribution of early-phase trials across the continuum of stroke care using published and ongoing trial examples. Finally, we highlight emerging innovations in early-phase trial design and application to inform future work in stroke.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/strokeaha.126.057817","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:00:22Z","timestamp":1790586022000},"page":"3451-3463","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Innovations in Early-Phase Adaptive Trial Designs for Stroke Research"],"prefix":"10.1161","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5240-3264","authenticated-orcid":true,"given":"Kathryn S.","family":"Hayward","sequence":"first","affiliation":[{"name":"Departments of Physiotherapy and Medicine (K.S.H.), University of Melbourne, Parkville, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3632-9433","authenticated-orcid":true,"given":"Bruce C.V.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Medicine (B.C.V.C., O.G., H.J., L.C.), University of Melbourne, Parkville, Australia."},{"name":"Department of Neurology, Royal Melbourne Hospital, Parkville, Australia (B.C.V.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-8530","authenticated-orcid":true,"given":"Emily J.","family":"Dalton","sequence":"additional","affiliation":[{"name":"Melbourne School of Health Sciences (E.J.D.), University of Melbourne, Parkville, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-1393","authenticated-orcid":true,"given":"Odkhishig","family":"Ganbold","sequence":"additional","affiliation":[{"name":"Department of Medicine (B.C.V.C., O.G., H.J., L.C.), University of Melbourne, Parkville, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-0504","authenticated-orcid":true,"given":"Hannah","family":"Johns","sequence":"additional","affiliation":[{"name":"Department of Medicine (B.C.V.C., O.G., H.J., L.C.), University of Melbourne, Parkville, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-3650","authenticated-orcid":true,"given":"Eva A.","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-1543","authenticated-orcid":true,"given":"Michael D.","family":"Hill","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, University of Calgary, Alberta, Canada (M.D.H.)."},{"name":"Clinical Neurosciences, Foothills Medical Centre, Calgary, Alberta, Canada (M.D.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-6606","authenticated-orcid":true,"given":"Leonid","family":"Churilov","sequence":"additional","affiliation":[{"name":"Department of Medicine (B.C.V.C., O.G., H.J., L.C.), University of Melbourne, Parkville, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/17474930241308142"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000213.pub3"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716405"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0296-z"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01148"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2021.101487"},{"key":"e_1_3_2_8_2","volume-title":"Adaptive designs for clinical trials E20","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2025","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Adaptive designs for clinical trials E20. 2025. Accessed May 29, 2026. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E20EWG_Step3_DraftGuideline_2025_0625_0.docx"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4088"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(24)00328-6"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2517623"},{"key":"e_1_3_2_12_2","unstructured":"The Grade Working Group. GRADE book (Version 1.0). Accessed May 30 2026. https:\/\/book.gradepro.org\/"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.124.048174"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.124.045754"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202003-192SD"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0034-3"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0262-9"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.124.048464"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1660"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.123.044060"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/15459683251338797"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/15459683211019362"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-023-01880-1"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.17.2095"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6949.248"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2026.06.005"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510061"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62227-8"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/1545968309331863"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2786"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.123.044144"},{"key":"e_1_3_2_33_2","unstructured":"Australian and New Zealand Clinical Trials Registry. ANZCTR data item definition\/explanation. Accessed May 29 2026. https:\/\/www.anzctr.org.au\/docs\/ANZCTR%20Data%20field%20explanation%20V7.pdf"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/10749357.2022.2035578"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.034348"},{"key":"e_1_3_2_36_2","unstructured":"US Food and Drug Administration. Step 3: clinical research. Accessed May 29 2026. https:\/\/www.fda.gov\/patients\/drug-development-process\/step-3-clinical-research#Clinical_Research_Phase_Studies"},{"key":"e_1_3_2_37_2","unstructured":"European Medicines Agency. CTIS public portal: Full trial information. Accessed May 29 2026. https:\/\/www.ema.europa.eu\/en\/documents\/other\/clinical-trial-information-system-ctis-public-portal-full-trial-information_en.pdf"},{"key":"e_1_3_2_38_2","unstructured":"Therapeutic Good Administration. Clinical trial handbook. Accessed May 29 2026. https:\/\/www.tga.gov.au\/resources\/guidance\/australian-clinical-trial-handbook#clinical-trial-phases-and-stages"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1191\/1740774506cn134oa"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1955"},{"key":"e_1_3_2_41_2","unstructured":"Zhou H Zhao Y Kuo YW Chen N Chen K Zhou Y Lee JJ Yuan Y. BOP2: Bayesian optimal phase II design with simple and complex endpoints. Accessed July 10 2025. https:\/\/biostatistics.mdanderson.org\/shinyapps\/BOP2\/"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7338"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00032"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/09622802231220497"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6094"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7674"},{"key":"e_1_3_2_47_2","unstructured":"Lin R Zhou Y Yuan Y. BOIN12: BAYESIAN optimal interval phase I\/II trial design for utility-based dose finding. Department of Biostatistics MD Anderson Cancer Centre. Accessed July 10 2025. https:\/\/biostatistics.mdanderson.org\/shinyapps\/BOIN12\/"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9337"},{"key":"e_1_3_2_49_2","unstructured":"National Institutes of Health. NIH definition of a clinical trial. 2017. Accessed March 29 2026. https:\/\/grants.nih.gov\/policy\/clinical-trials\/definition.htm"},{"key":"e_1_3_2_50_2","volume-title":"Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry","author":"US Food and Drug Administration","year":"2019","unstructured":"US Food and Drug Administration. Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry. US Food and Drug Administration; 2019."},{"key":"e_1_3_2_51_2","volume-title":"Multiple Endpoints in Clinical Trials Guidance for Industry","author":"US Food and Drug Administration","year":"2022","unstructured":"US Food and Drug Administration. Multiple Endpoints in Clinical Trials Guidance for Industry. US Food and Drug Administration; 2022."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102987"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102988"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076386"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076387"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12548"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.09.022"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2017.02.007"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.026318"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2025-001212"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1177\/1747493020967256"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209876"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","unstructured":"Ganbold O Hayward KS Johns H Campbell BCV Churilov L. A protocol of systematic scoping review of early-phase stroke trials testing multidimensional pharmacological behavioural device and biologic interventions. Open Sci Framework. 2026. doi: 10.17605\/OSF.IO\/P4TZ7","DOI":"10.17605\/OSF.IO\/P4TZ7"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00044-4"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1177\/15459683211019362"},{"key":"e_1_3_2_66_2","volume-title":"Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry","author":"US Food and Drug Administration","year":"2022","unstructured":"US Food and Drug Administration. Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry. 2022."},{"key":"e_1_3_2_67_2","volume-title":"Master Protocols for Drug and Biological Product Development. Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research","author":"US Food and Drug Administration","year":"2026","unstructured":"US Food and Drug Administration. Master Protocols for Drug and Biological Product Development. Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research. US Food and Drug Administration; 2026."},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3664-1"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01625"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.126.057817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:01:23Z","timestamp":1793037683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.126.057817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1161\/STROKEAHA.126.057817"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.126.057817","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"2026-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}